| 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the … M Kita, RJ Fox, R Gold, G Giovannoni, JT Phillips, SP Sarda, J Kong, ... CLINICAL THERAPEUTICS 40 (5), 812-812, 2018 | | 2018 |
| “Double whammy” neuropathy: a 37-year-old woman with burning and weakness in both legs SJ Hickman, A Sanyal, H Manji, MJ Groves, G Giovannoni The Lancet Neurology 5 (7), 632-636, 2006 | | 2006 |
| “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis G Giovannoni, D Tomic, JR Bright, E Havrdová Multiple Sclerosis Journal 23 (9), 1179-1187, 2017 | 176 | 2017 |
| “Rocking the boat” with a new drug for neuromyelitis optica spectrum disorder M Levy, J Lechner-Scott, C Hawkes, G Giovannoni Multiple Sclerosis and Related Disorders 44, 2020 | | 2020 |
| (DMT04) Treatment-Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis. J Oh, B Walker, G Giovannoni, D Jack, F Dangond, A Nolting, J Aldridge, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT08) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study. B Singer, G Giovannoni, N De Stefano, M Mandel, Y Hyvert, J Aldridge, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT10) Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis Independent of Relapse Activity: Results from the Phase 3 EXPAND Study. BAC Cree, RJ Fox, G Giovannoni, P Vermersch, A Bar-Or, R Gold, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT22) Characterization of Incidence and Time-to-Recovery from Grade 3/4 Lymphopenia Lasting= 6 Months in Patients with Multiple Sclerosis Treated with Cladribine Tablets. G Pardo, K Rammohan, TP Leist, J Aldridge, C Rossier, A Nolting, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT26) Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies. G Giovannoni, G Comi, K Rammohan, P Rieckmann, P Vermersch, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT27) Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets. G Giovannoni, PK Coyle, P Vermersch, B Walker, J Aldridge, A Nolting, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT34) Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-Week Timepoint (CLARITY) Using Deconvolution Algorithms. I Kalatskaya, G Giovannoni, TP Leist, P Soelberg-Sorensen, U Boschert, ... International Journal of MS Care 22, 2020 | 1 | 2020 |
| (DXT42) Rationale and Design of CLASSIC-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets. A Boyko, J Correale, G Edan, MS Freedman, G Giovannoni, X Montalban, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT49) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Aged Over and Under 30 Years in the CLARITY Study. MS Freedman, G Pardo, N De Stefano, J Aldridge, S Syed, Y Hyvert, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT58) Reduction of Risk of Secondary Progressive Multiple Sclerosis within 2 Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study. P Vermersch, G Giovannoni, P Soelberg-Sorensen, K Rammohan, ... International Journal of MS Care 22, 2020 | | 2020 |
| (DXT73) Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Postapproval Data. S Cook, G Giovannoni, TP Leist, G Comi, S Syed, A Nolting, D Damian, ... International Journal of MS Care 22, 2020 | 1 | 2020 |
| (DXT74) An Analysis of the Relationship Between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis. S Cook, G Giovannoni, TP Leist, G Comi, A Nolting, E Sylvester, D Jack, ... International Journal of MS Care 22, 2020 | | 2020 |
| (QOL15) Multiple Sclerosis Management and Expanded Disability Status Scale: A Great Start, but a Reason for Change Was Never So Apparent and Needed. M Gudesblatt, J Srinivasan, O Kaczmarek, T Drost, B Bumstead, L Fafard, ... International Journal of MS Care 22, 2020 | | 2020 |
| [Retracted] Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies CE Teunissen, H Tumani, JL Bennett, FS Berven, L Brundin, ... Multiple sclerosis international 2011 (1), 246412, 2011 | 87 | 2011 |
| 010 Safety and efficacy of long-term dimethyl fumarate treatment R Gold, G Giovannoni, JT Phillips, A Bar-Or, RJ Fox, C Chen, B Parks, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A16-A17, 2022 | | 2022 |
| 015 Reduced risk of secondary progressive multiple sclerosis by treatment with clad-ribine tablets: CLARITY study analysis P Vermersch, G Giovannoni, P Soelberg-Sorensen, K Rammohan, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A18-A18, 2022 | | 2022 |
Ludwig KapposUniversity Hospital Basel在 uhbs.ch 的电子邮件经过验证
